deferoxamine has been researched along with Stroke in 15 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Stroke: A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Despite transferrin being the main circulating carrier of iron in body fluids, and iron overload conditions being known to worsen stroke outcome through reactive oxygen species (ROS)-induced damage, the contribution of blood transferrin saturation (TSAT) to stroke brain damage is unknown." | 9.27 | Iron-loaded transferrin (Tf) is detrimental whereas iron-free Tf confers protection against brain ischemia by modifying blood Tf saturation and subsequent neuronal damage. ( Alborch, E; Castelló-Ruiz, M; Castillo, J; Dávalos, A; DeGregorio-Rocasolano, N; García-Yébenes, I; Gasull, T; Guirao, V; Lizasoain, I; Martí-Sistac, O; Millán, M; Ponce, J; Ramos-Cabrer, P; Salom, JB, 2018) |
| "After 8 weeks of type 2 diabetes induced by a combination of high-fat diet and low-dose streptozotocin, male control and diabetic animals were subjected to thromboembolic middle cerebral artery occlusion (MCAO) and randomized to vehicle, DFX, or tPA/DFX and followed for 14 days with behavioral tests." | 5.62 | Deferoxamine Treatment Prevents Post-Stroke Vasoregression and Neurovascular Unit Remodeling Leading to Improved Functional Outcomes in Type 2 Male Diabetic Rats: Role of Endothelial Ferroptosis. ( Abdelsaid, M; Abdul, Y; Dong, G; Ergul, A; Fagan, SC; Hafez, S; Jamil, S; Johnson, MH; Li, W; Ward, R; Wolf, V, 2021) |
| " Thus, low-dose chronic administration of DFO or DFR induced a prolonged neuroprotective state independent of HIF-1 function." | 5.37 | Prophylactic neuroprotection against stroke: low-dose, prolonged treatment with deferoxamine or deferasirox establishes prolonged neuroprotection independent of HIF-1 function. ( Rempe, DA; Zhao, Y, 2011) |
| "Deferoxamine (DFO) is a high-affinity iron chelator approved by the Food and Drug Administration for treating iron overload." | 5.35 | Intranasal deferoxamine provides increased brain exposure and significant protection in rat ischemic stroke. ( Coppes, VG; Frey, WH; Hanson, LR; Hoekman, JD; Marti, DL; Martinez, PM; Matthews, RB; Panter, SS; Rao, RJ; Roeytenberg, A; Sweet, DC, 2009) |
| "Despite transferrin being the main circulating carrier of iron in body fluids, and iron overload conditions being known to worsen stroke outcome through reactive oxygen species (ROS)-induced damage, the contribution of blood transferrin saturation (TSAT) to stroke brain damage is unknown." | 5.27 | Iron-loaded transferrin (Tf) is detrimental whereas iron-free Tf confers protection against brain ischemia by modifying blood Tf saturation and subsequent neuronal damage. ( Alborch, E; Castelló-Ruiz, M; Castillo, J; Dávalos, A; DeGregorio-Rocasolano, N; García-Yébenes, I; Gasull, T; Guirao, V; Lizasoain, I; Martí-Sistac, O; Millán, M; Ponce, J; Ramos-Cabrer, P; Salom, JB, 2018) |
| " We report baseline LIC results from the TWiTCH trial, which compares hydroxyurea with blood transfusion treatment for primary stroke prophylaxis assessed by transcranial Doppler sonography in pediatric SCA patients." | 5.20 | Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial. ( Cohen, AR; Davis, BR; Heeney, MM; Kwiatkowski, JL; Lee, MT; Odame, I; Owen, WC; Pressel, S; Rogers, ZR; Schultz, WH; St Pierre, T; Ware, RE; Wood, JC, 2015) |
| "These results suggest that superoxide anions in the RVLM, which generate hydroxyl radicals, are increased in SHRSP and contribute to the neural mechanisms of hypertension in SHRSP." | 3.72 | Increased reactive oxygen species in rostral ventrolateral medulla contribute to neural mechanisms of hypertension in stroke-prone spontaneously hypertensive rats. ( Hirooka, Y; Ito, K; Kimura, Y; Kishi, T; Shimokawa, H; Takeshita, A, 2004) |
| "After 8 weeks of type 2 diabetes induced by a combination of high-fat diet and low-dose streptozotocin, male control and diabetic animals were subjected to thromboembolic middle cerebral artery occlusion (MCAO) and randomized to vehicle, DFX, or tPA/DFX and followed for 14 days with behavioral tests." | 1.62 | Deferoxamine Treatment Prevents Post-Stroke Vasoregression and Neurovascular Unit Remodeling Leading to Improved Functional Outcomes in Type 2 Male Diabetic Rats: Role of Endothelial Ferroptosis. ( Abdelsaid, M; Abdul, Y; Dong, G; Ergul, A; Fagan, SC; Hafez, S; Jamil, S; Johnson, MH; Li, W; Ward, R; Wolf, V, 2021) |
| " Thus, low-dose chronic administration of DFO or DFR induced a prolonged neuroprotective state independent of HIF-1 function." | 1.37 | Prophylactic neuroprotection against stroke: low-dose, prolonged treatment with deferoxamine or deferasirox establishes prolonged neuroprotection independent of HIF-1 function. ( Rempe, DA; Zhao, Y, 2011) |
| "Deferoxamine (DFO) is a high-affinity iron chelator approved by the Food and Drug Administration for treating iron overload." | 1.35 | Intranasal deferoxamine provides increased brain exposure and significant protection in rat ischemic stroke. ( Coppes, VG; Frey, WH; Hanson, LR; Hoekman, JD; Marti, DL; Martinez, PM; Matthews, RB; Panter, SS; Rao, RJ; Roeytenberg, A; Sweet, DC, 2009) |
| "The stroke was ischemic in all individuals and the first cerebrovascular event occurred before 6 years of age; 3 patients had recurrence of stroke despite prophylactic blood transfusion therapy and both cerebral hemispheres were affected in 4 patients." | 1.35 | Stroke in patients with sickle cell disease: clinical and neurological aspects. ( Ciasca, SM; Moura-Ribeiro, MV; Oliveira, CC, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (33.33) | 29.6817 |
| 2010's | 6 (40.00) | 24.3611 |
| 2020's | 4 (26.67) | 2.80 |
| Authors | Studies |
|---|---|
| Li, W | 2 |
| Abdul, Y | 2 |
| Chandran, R | 1 |
| Jamil, S | 2 |
| Ward, RA | 1 |
| Abdelsaid, M | 2 |
| Dong, G | 2 |
| Fagan, SC | 2 |
| Ergul, A | 2 |
| Sakamuri, SSVP | 1 |
| Sure, VN | 1 |
| Katakam, PVG | 1 |
| Sun, T | 1 |
| Zhao, YY | 1 |
| Xiao, QX | 1 |
| Wu, M | 1 |
| Luo, MY | 1 |
| Ward, R | 1 |
| Hafez, S | 1 |
| Wolf, V | 1 |
| Johnson, MH | 1 |
| DeGregorio-Rocasolano, N | 1 |
| Martí-Sistac, O | 1 |
| Ponce, J | 1 |
| Castelló-Ruiz, M | 1 |
| Millán, M | 1 |
| Guirao, V | 1 |
| García-Yébenes, I | 1 |
| Salom, JB | 1 |
| Ramos-Cabrer, P | 1 |
| Alborch, E | 1 |
| Lizasoain, I | 1 |
| Castillo, J | 1 |
| Dávalos, A | 1 |
| Gasull, T | 1 |
| Gelosa, P | 1 |
| Pignieri, A | 1 |
| Gianazza, E | 1 |
| Criniti, S | 1 |
| Guerrini, U | 1 |
| Cappellini, MD | 1 |
| Banfi, C | 1 |
| Tremoli, E | 1 |
| Sironi, L | 1 |
| Wood, JC | 2 |
| Pressel, S | 1 |
| Rogers, ZR | 1 |
| Odame, I | 1 |
| Kwiatkowski, JL | 2 |
| Lee, MT | 2 |
| Owen, WC | 1 |
| Cohen, AR | 1 |
| St Pierre, T | 1 |
| Heeney, MM | 1 |
| Schultz, WH | 1 |
| Davis, BR | 1 |
| Ware, RE | 1 |
| Hanson, LR | 1 |
| Roeytenberg, A | 1 |
| Martinez, PM | 1 |
| Coppes, VG | 1 |
| Sweet, DC | 1 |
| Rao, RJ | 1 |
| Marti, DL | 1 |
| Hoekman, JD | 1 |
| Matthews, RB | 1 |
| Frey, WH | 1 |
| Panter, SS | 1 |
| Adamkiewicz, TV | 1 |
| Abboud, MR | 1 |
| Paley, C | 1 |
| Olivieri, N | 1 |
| Kirby-Allen, M | 1 |
| Vichinsky, E | 1 |
| Casella, JF | 1 |
| Alvarez, OA | 1 |
| Barredo, JC | 1 |
| Iyer, RV | 1 |
| Kutlar, A | 1 |
| McKie, KM | 1 |
| McKie, V | 1 |
| Odo, N | 1 |
| Gee, B | 1 |
| Woods, GM | 1 |
| Coates, T | 1 |
| Wang, W | 1 |
| Adams, RJ | 1 |
| Inati, A | 1 |
| Musallam, KM | 1 |
| Taher, AT | 1 |
| Zhao, Y | 1 |
| Rempe, DA | 1 |
| Chaudhary, N | 1 |
| Gemmete, JJ | 1 |
| Thompson, BG | 1 |
| Xi, G | 1 |
| Pandey, AS | 1 |
| Kishi, T | 1 |
| Hirooka, Y | 1 |
| Kimura, Y | 1 |
| Ito, K | 1 |
| Shimokawa, H | 1 |
| Takeshita, A | 1 |
| Oliveira, CC | 1 |
| Ciasca, SM | 1 |
| Moura-Ribeiro, MV | 1 |
| Wayne, AS | 1 |
| Schoenike, SE | 1 |
| Pegelow, CH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00000592] | Phase 3 | 0 participants | Interventional | 1994-07-31 | Completed | ||
| [NCT00006182] | Phase 3 | 0 participants | Interventional | 2000-07-31 | Completed | ||
| Safety and Effectiveness Study of Deferoxamine and Xingnaojing Injection in Intracerebral Hemorrhage[NCT02367248] | Phase 1/Phase 2 | 180 participants (Anticipated) | Interventional | 2015-03-31 | Recruiting | ||
| Nonmyeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Severe Congenital Anemias Including Sickle Cell Disease (SCD) and B-Thalassemia[NCT00061568] | Phase 1/Phase 2 | 150 participants (Anticipated) | Interventional | 2004-07-16 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for deferoxamine and Stroke
| Article | Year |
|---|---|
Deferoxamine in intracerebral hemorrhage: Systematic review and meta-analysis.
Topics: Cerebral Hemorrhage; Deferoxamine; Hematoma; Humans; Siderophores; Stroke | 2023 |
3 trials available for deferoxamine and Stroke
11 other studies available for deferoxamine and Stroke
| Article | Year |
|---|---|
Deferoxamine prevents poststroke memory impairment in female diabetic rats: potential links to hemorrhagic transformation and ferroptosis.
Topics: Animals; Deferoxamine; Diabetes Mellitus, Experimental; Female; Ferroptosis; Hemin; Male; Rats; Stro | 2023 |
Iron chelation therapy to prevent poststroke cognitive impairments: role of diabetes and sex.
Topics: Animals; Chelation Therapy; Cognitive Dysfunction; Deferoxamine; Diabetes Mellitus, Experimental; Fe | 2023 |
Deferoxamine Treatment Prevents Post-Stroke Vasoregression and Neurovascular Unit Remodeling Leading to Improved Functional Outcomes in Type 2 Male Diabetic Rats: Role of Endothelial Ferroptosis.
Topics: Animals; Deferoxamine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Endothelial Cells | 2021 |
Altered iron homeostasis in an animal model of hypertensive nephropathy: stroke-prone rats.
Topics: Animals; Blood Pressure; Deferoxamine; Disease Models, Animal; Hemolysis; Homeostasis; Hypertension, | 2013 |
Intranasal deferoxamine provides increased brain exposure and significant protection in rat ischemic stroke.
Topics: Administration, Intranasal; Animals; Behavior, Animal; Brain; Brain Ischemia; Deferoxamine; Dose-Res | 2009 |
Iron overload indices rise linearly with transfusion rate in patients with sickle cell disease.
Topics: Alanine Transaminase; Anemia, Sickle Cell; Area Under Curve; Child; Deferoxamine; Ferritins; Humans; | 2010 |
Prophylactic neuroprotection against stroke: low-dose, prolonged treatment with deferoxamine or deferasirox establishes prolonged neuroprotection independent of HIF-1 function.
Topics: Animals; Astrocytes; Benzoates; Brain; Cyclic AMP Response Element-Binding Protein; Deferasirox; Def | 2011 |
Iron--potential therapeutic target in hemorrhagic stroke.
Topics: Cerebral Hemorrhage; Deferoxamine; Humans; Iron; Iron Chelating Agents; Nerve Degeneration; Stroke | 2013 |
Increased reactive oxygen species in rostral ventrolateral medulla contribute to neural mechanisms of hypertension in stroke-prone spontaneously hypertensive rats.
Topics: 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt; Animals; Blood Pressure; Brain Chemistry; Ca | 2004 |
Stroke in patients with sickle cell disease: clinical and neurological aspects.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Blood Transfusion; Child; Deferoxamine; Female; Humans; Inte | 2008 |
Financial analysis of chronic transfusion for stroke prevention in sickle cell disease.
Topics: Adolescent; Anemia, Sickle Cell; Child; Cost-Benefit Analysis; Deferoxamine; Erythrocyte Transfusion | 2000 |